Abstract
At major annual oncology meetings, many presentations about phase III clinical trials that failed to hit their primary endpoints emphasized seemingly positive results of questionable statistical rigor or unclear clinical relevance, a study concludes.
Full Text 
Sign-in/Register to access full text options
Sign-in/Register to access full text options 
Published version (
Free)
Free) 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
